CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is based in Irvine, California.

CG Oncology, Inc.

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on CG Oncology, Inc., with a price target of $85.00. Roy covers th...

CG Oncology, Inc. (CGON) Gets a Buy from JonesTrading

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc., with a price target of $108.00. Accordin...

LifeSci Capital Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gain Therapeutics (GANX) and CG Oncology, Inc. (CGON...

Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Entrada Therapeutics Inc (TRDA) and CG Oncology, Inc...

Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on CG Oncology, Inc., with a price target of $72...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CGON	$67.77	-1.15%	752.57K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CGON	$67.77	-1.2%	752.57K
3
4
5
6

CGON

CGON

No Data Available

Get CG Oncology, Inc. Data in Excel

Get CG Oncology, Inc. Data in Excel